Claims for Patent: 7,932,273

Summary for Patent: 7,932,273

Title:	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino- ]propionic acid ethylester methansulfonate and its use as a medicament
Abstract:	Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-m- ethyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.
Inventor(s):	Schmid; Rolf (Baltringen, DE), Sieger; Peter (Mittelbiberach, DE), Sobotta; Rainer (Ingelheim am Rhein, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:	12/022,655
Patent Claims:	1. A polymorph form II of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylami- no]propionate methanesulfonate, wherein the polymorph has a melting point of T.sub.mp=190.degree. C..+-.3.degree. C., determined by DSC, evaluation by peak maximum, at a heating rate of 10.degree. C/min and possesses an X-ray powder diffraction pattern which comprises characteristic peaks as expressed in FIG. 1 (form II). 2. A pharmaceutical composition comprising: (a) ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl }-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate according to claim 1; and (b) one or more inert carriers and/or diluents.